Mike Crackower

Company: Ventus Therapeutics

Job title: Chief Scientific Officer

Seminars:

Exploring the Non-Canonical Caspase-4 Inhibitor as a Novel Target for Inhibiting the Inflammasome 11:00 am

 Session Details TBCRead more

day: Day 1

Examining Structurally Differentiated VENT-02 & Brain-Penetrant NLRP3 Inhibitor for Treatment of Neuroinflammatory Diseases 8:30 am

Exploring the unique structural characteristics of VENT-02, a novel NLRP3 inhibitor designed for neuroinflammatory diseases Investigating the potential of VENT-02 as a brain-penetrant therapeutic agent targeting the NLRP3 inflammasome Assessing the preclinical data supporting the efficacy and safety profile of VENT-02 in treating neuroinflammatory conditionsRead more

day: Day 1